Regen BioPharma Inc (RGBP)

[29YEARINVESTOR]

Who ever it is they are making my account look very good today!
Day Change +$82,912.88
If It is not future canary financiers or those in the know at Cornell!
My thoughts is slow steady short covering by MM’s before the News hits!
They seem to find out about the news way before we get it.
There should be a lot bigger Volume along with much faster covering and higher moves up.
Once MM’s know the news is fixing to be announced.

Dr. David Koo’s Making RGBP Great Again!
https://docoh.com/patent/by/companyId/1589150

KOO’s owns 169+ million shares of RGBPP preferred shares or 169 million reasons to see that RGBP is successful.
https://www.marketscreener.com/business-leaders/David-Raymond-Koos-06H0YV-E/biography/

Big News and Advancements

$RGBP to our knowledge is the only Stem Cell company to make the advancements, get this far, successfully with NR2F6.

Regen has Big Name Partners such as Eli Lilly, the NIH, Weill Cornell Medical College (part of Cornell University), Pan Am Cancer Research & Treatment Center, and the Newest - Chem Div.

Hope you all understand we are dealing with a drug that will be designed to be internationally approved in:

EUROPE
USA
JAPAN

In the US alone it will cost around 70m to go through FDA trials.

70m x 3 = approx 210m in investments alone $RGBP pic.twitter.com/HfxniiAgZw

— Galfy (@GalfyStocks) November 12, 2021

https://www.marketwatch.com/investing/secfile/15347408

https://www.prnewswire.com/news-releases/regen-biopharma-inc-announces-signing-of-a-letter-of-intent-to-acquire-an-in-vitro-diagnostics-start-up-company-canary-oncoceutics-inc-which-is-developing-functional-cancer-tests-for-personalized-medicine-301427159.html

New Partners – NIH (NCATS) - Pan Am Cancer Research and Treatment Center - Eli Lily & Company –

Weill Cornell Medical College (Cornell University)

https://news.weill.cornell.edu/news/2022/01/lymphoma-cell-metabolism-may-provide-new-cancer-target